Gyre Therapeutics (GYRE) Gains from Investment Securities (2015 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Gains from Investment Securities of -$89000.0 for Q1 2026, up 96.05% year-over-year from -$45395.8 in Q1 2025, and up 66.16% quarter-over-quarter from -$263000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Gains from Investment Securities for 4 consecutive years, with -$89000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 96.05% year-over-year to -$89000.0; the TTM figure through Mar 2026 stood at -$541000.0 (up 89.46% YoY), while the FY2025 annual figure was -$2.7 million, up 62.23% from the prior year.
- Gains from Investment Securities improved to -$89000.0 in Q1 2026 per GYRE's latest filing, from -$263000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $228000.0 in Q3 2024 and bottomed at -$4.3 million in Q1 2024.
- Historically, Gains from Investment Securities has averaged -$1.1 million across 3 years, with a median of -$212000.0 in 2025.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities slumped 89.91% — and 2026, when it jumped 96.05%.
- Gyre Therapeutics' Gains from Investment Securities stood at -$194000.0 in 2024, then slumped by 35.57% to -$263000.0 in 2025, then jumped by 66.16% to -$89000.0 in 2026.
- Business Quant data shows GYRE's Gains from Investment Securities at -$89000.0 in Q1 2026, -$263000.0 in Q4 2025, and $23000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -89,000.00 |
| Dec 31, 2025 | -263,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Mar 31, 2025 | -2.26 Mn |
| Dec 31, 2024 | -194,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Sep 30, 2015 | 504,000.00 |
| Jun 30, 2015 | -517,000.00 |
| Mar 31, 2015 | -78,000.00 |